Hepatitis B immunisation for adults with end-stage kidney disease

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

Primary objectives
We aim to evaluate the beneficial and harmful effects of:

hepatitis B immunisation in people with end-stage kidney disease.

Secondary objectives
We aim to evaluate the beneficial and harmful effects of:

reinforced vaccination series (three doses plus one additional booster) versus traditional triple inoculations; and

intradermal versus intramuscular hepatitis B vaccination, in people with end-stage kidney disease.

This is a protocol.

Published:

9 May 2023

Authors:

Borges do Nascimento IJ, Pac A, Zanghelini F, Civile VT, Correa NE, Abdulazeem HM

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Borges do Nascimento IJ, Pac A, Zanghelini F, Civile VT, Correa NE, Abdulazeem HM. Hepatitis B immunisation for adults with end-stage kidney disease (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No.: CD014764. DOI: 10.1002/14651858.CD014764.